EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Status:
Terminated
Trial end date:
2012-01-10
Target enrollment:
Participant gender:
Summary
An experimental drug called EZN-3042 targets survivin, a protein expressed in leukemia cells
at relapse that promotes the leukemia cells to grow. The main goal of this phase I study is
to find out the dose of EZN-3042 that can be safely given without serious side effects both
alone and in combination with standard chemotherapy drugs during re-induction.
Phase:
Phase 1
Details
Lead Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium